PMC:4134656 / 14811-15337 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4134656","sourcedb":"PMC","sourceid":"4134656","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4134656","text":"In the proliferative phase of IH there is an increased expression of pro-angiogenic factors in particular the vascular endothelial growth factors (VEGF) and basic fibroblast growth factors (bFGF). The intermediate effects of propranolol are due to a downregulation of both VEGF and bFGF resulting in inhibition of proangiogenic cascade and angiogenesis. The long term effect of propranolol is due to apoptosis resulting in regression of haemangiomas.[41] This may be the reason for its use in the post proliferative phase.[41]","tracks":[{"project":"2_test","denotations":[{"id":"25136206-20456345-58659562","span":{"begin":451,"end":453},"obj":"20456345"},{"id":"25136206-20456345-58659563","span":{"begin":523,"end":525},"obj":"20456345"}],"attributes":[{"subj":"25136206-20456345-58659562","pred":"source","obj":"2_test"},{"subj":"25136206-20456345-58659563","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#eca793","default":true}]}]}}